Panchsheel Organics Ltd.
Snapshot View

231.95 +4.60 ▲2.0%

18 May 2022, 04:01:00 PM
Volume: 17,237

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.panchsheel.com
Market Cap 232.66 Cr.
Enterprise Value(EV) 226.53 Cr. 2021-09
Financial Indicators
Earnings per share (EPS) 6.24 Trailing Twelve Months Ending 2021-12
Price-Earning Ratio (PE) 37.19 Trailing Twelve Months Ending 2021-12
Industry PE 28.96 Trailing Twelve Months Ending 2021-12
Book Value / Share 49.95 Trailing Twelve Months Ending 2021-12
Price to Book Value 4.64 Calculated using Price: 231.95
Dividend Yield 0.00 Period Ending 2021-03
No. of Shares Subscribed 1.00 Cr. 10,030,800 Shares
FaceValue 10
Company Profile

Panchsheel Organics, incorporated in the year 1989, is a part of the Pharmaceutical Division of the Turakhia Brothers Group. Turakhia Brothers was founded in 1975 in the Mumbai, India. The Turakhia Group, promoters of the company, are engaged in the import-export trade of pharmaceutical raw materials since the past 25 years.

Panchsheel exports bulk actives to over 60 countries mainly in Europe, South East Asia, Japan and Latin America. The company's inherent strength lies in identifying relevant bulk drugs and selling them at affordable prices across the world.

Skilled people, modern equipment and broad experience contribute to the strength of Panchsheel Organics. Skilled production teams assure flexibility, efficiency and consistent standard in drugs manufacturing.

The R & D division of Panchsheel backed with experienced, highly qualified  teams provide sophisticated innovative solutions. Skilled production teams assure flexibility, efficiency and consistent standard in chemical manufacturing.

The current practices at Panchsheel are adherence to high quality and safety standards as well as full compliance with GMP procedures. The gaseous emissions are properly controlled and waste water is treated properly so as to ensure compliance with local and international risk, minimizing damage to persons and environment.

Panchsheel has free capacity in its five production sites in all over India. This capacity is would be used by interested companies for development and custom synthesis on strictly confidential terms.

Some of the basic operations carried out by Panchsheel are:

  • Hydrolysis
  • Condensation
  • Oxidation
  • Hydrogenation
  • Friedel Crafts
  • Grignard
  • Esterification
  • Nitration

Product range of the company includes:

  • Bulk Drugs - Alendronate Sodium Trihydrate,  Isoxsuprine HCL, Alprazolam, Itraconazole Pellets 22%, Amitriptyline HCL BP/USP, Ketoconazole BP/USP, Amlodipine Besylate etc.
  • Bittering Agent
  • Novel Drug Delivery System
  • Phytochemicals & Herbal Products

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+2.02%
1 Week
+17.83%
1 Month
+36.80%
3 Month
+52.75%
6 Month
+137.78%
1 Year
+372.60%
2 Year
+935.49%
5 Year
+332.34%
10 Year
+2628.82%
9 years 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 8.01 10.49 10.55 15.43 14.48 14.57 14.05 16.08 13.35
Return on Capital Employed (%) 11.05 15.09 14.28 18.51 19.66 18.21 17.77 20.31 18.60
Return on Assets (%) 4.11 5.22 5.55 8.66 8.43 8.55 8.76 10.79 8.94

Balance Sheet View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-09* Rs. Cr.
Shh. Funds 16 18 19 21 23 27 30 35 40 43
Non Curr. Liab. 2 3 4 4 2 1 0 1 2 2
Curr. Liab. 14 15 11 12 14 19 15 17 18 16
Minority Int.
Equity & Liab. 32 35 33 37 39 47 45 53 59 61
Non Curr. Assets 8 8 7 9 10 10 9 11 15 9
Curr. Assets 24 27 26 28 29 37 36 42 45 52
Misc. Exp. not W/O
Total Assets 32 35 33 37 39 47 45 53 59 61

Profit Loss View Details

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2021-12 Rs. Cr. TTM
Net Sales 33 39 36 40 40 42 48 51 49 58
Other Income 0 0 0 0 0 0 0 0 0 0
Total Income 33 39 36 41 40 42 49 51 50 58
Total Expenditure -30 -35 -31 -35 -33 -36 -41 -42 -41 -48
PBIDT 3 5 5 6 7 7 7 9 9 11
Interest -1 -1 -1 -1 0 -1 0 0 0 0
Depreciation -1 -1 -1 -1 -1 -1 -1 -1 -1 -1
Taxation -1 -1 -1 -1 -2 -2 -2 -2 -2 -3
Exceptional Items
PAT 1 2 2 3 3 4 4 5 5 6
Adjusted EPS 1 2 2 3 3 4 4 5 5 6

Cash Flow View Details

Particulars 10 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 1 1 3 1 3 5 3 2 5 5
Cash Fr. Inv. 0 -1 -1 -1 -2 -3 -1 -1 -3 -1
Cash Fr. Finan. -2 0 -2 0 -1 -1 -2 -2 -1 -2
Net Change -1 0 0 0 -1 0 0 0 1 3
Cash & Cash Eqvt 0 0 1 0 1 1 0 1 2 4

Shareholding Pattern View Details

9 Qtrs 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%)
Promoter 68.22 68.22 68.22 68.22 68.22 68.22 68.22 68.22 68.22
Public 31.78 31.78 31.78 31.78 31.78 31.78 31.78 31.78 31.78
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Sat, 14 May 2022
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.

Sr. No. Particulars Details
1 Name of Company PANCHSHEEL ORGANICS LTD.
2 CIN NO. L24232MP1989PLC005390
3 Report filed for FY 2021-2022
Details of the Current block (all figures in Rs crore):
4 2 - year block period (Specify financial years)* 2020-21 2021-22
5 Incremental borrowing done in FY (T)(a) 0.00
6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00
7 Actual borrowing done through debt securities in FY (T)(c) 0.00
8 Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d) 0
8Quantum of (d) which has been met from (c)(e)* 0
9 Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}* 0


Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):
2 - year Block period (Specify financial years)2020-21 2021-22
Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#0.00



Name of the Company Secretary :-NIKHIL BORANA
Designation :-COMPANY SECRETARY AND COMPLIANCE OFFICER
Name of the Chief Financial Officer :- CHANDRAKANT SHAH
Designation : -Chief Financial Officer

Date: 14/05/2022

Sat, 07 May 2022
Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to the provisions of Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find enclosed herewith the copies of the newspaper advertisement of the Notice of the 1st Extra-ordinary General Meeting of the Company for the financial year 2022-23 to be held on Friday May 27 2022 published on May 6 2022 in Business Standard newspaper in Hindi and English language.The aforesaid newspaper clippings are also available on website of the Company www.panchsheelorgancis.com.Kindly take the same on record.
Thu, 05 May 2022
Notice Of Extra-Ordinary General Meeting To Be Held On May 27 2022
Notice convening the Extra-ordinary General Meeting of the members of the Company for the financial year 2022-23 scheduled to be held on Friday May 27 2022

Technical Scans View Details

Wed, 18 May 2022
Close Crossing 52 Week High Close Crossing 52 Week High
Opening at High Opening at High
Closing Above Previous High Closing Above Previous High
Closing Above Previous High For 3 Days Closing Above Previous High For 3 Days
Making Higher Highs for 3 days Making Higher Highs for 3 days

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 215,700.21 899.00 +0.8%
Divi's Laboratories Ltd. 115,623.51 4,355.45 +1.2%
Cipla Ltd. 76,889.38 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. 65,126.60 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. 53,689.19 3,734.00 -2.1%
Gland Pharma Ltd. 51,396.43 3,122.95 +0.6%
Piramal Enterprises Ltd. 47,255.41 1,980.00 -0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 33.47 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-12 45.03 4,355.45 +1.2%
Cipla Ltd. Consolidated 2022-03 30.55 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-12 24.64 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 47.37 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-12 43.33 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-12 38.03 1,980.00 -0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-12 4.17 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-12 10.67 4,355.45 +1.2%
Cipla Ltd. Consolidated 2022-03 3.69 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-12 3.39 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-12 9.70 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-12 7.48 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-12 1.33 1,980.00 -0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 0.08 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 0.10 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 0.62 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 0.00 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 1,980.00 -0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 14.13 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,980.00 -0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.98 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 14.13 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 3.44 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 20.97 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 1,980.00 -0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 33,498.14 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 10,560.00 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 3,462.88 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 1,980.00 -0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 2,284.68 899.00 +0.8%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,355.45 +1.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 953.00 +1.6%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 3,913.25 +0.2%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 136.00 3,734.00 -2.1%
Gland Pharma Ltd. Consolidated 2021-03 996.96 3,122.95 +0.6%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 1,980.00 -0.2%